Replimune (REPL) Research & Development (2017 - 2026)

Replimune has reported Research & Development for 10 years, with the latest figure at $52.3 million in Q1 2026.

• Quarterly Research & Development fell 3.06% year-over-year to $52.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.2 million (up 17.4% YoY) and the FY2026 annual result came in at $221.2 million, up 16.75% from the prior year.
• Research & Development fell to $52.3 million in Q1 2026 per REPL's latest filing, from $53.1 million in the prior quarter.
• Over five years, Research & Development peaked at $57.9 million in Q3 2025 and troughed at $21.7 million in Q1 2022.
• A 5-year average of $43.1 million and a median of $43.0 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development soared 74.61% in 2023, then fell 11.51% in 2024.
• Over 5 years, Research & Development stood at $30.3 million in 2022, then surged by 41.59% to $42.8 million in 2023, then grew by 12.04% to $48.0 million in 2024, then rose by 10.7% to $53.1 million in 2025, then dropped by 1.54% to $52.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $52.3 million, $53.1 million, and $57.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.